Entrada Therapeutics Inc Capital Reinvestment Ratio
Entrada Therapeutics Inc capital reinvestment ratio. Entrada Therapeutics Inc (TRDA) has a Capital Reinvestment Ratio of 0.03x as of June 2024, meaning it reinvests 0% of its operating cash flow ($39.83 Million) in capital expenditures ($1.05 Million). Check TRDA cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Entrada Therapeutics Inc (2023–2023)
Capital reinvestment ratio of Entrada Therapeutics Inc from 2023 to 2023. This chart tracks Entrada Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. Also explore Entrada Therapeutics Inc net asset momentum to track the company's year-over-year net asset growth rate.
Entrada Therapeutics Inc Capital Reinvestment Ratio by Year (2023–2023)
Entrada Therapeutics Inc capital reinvestment ratio by year from 2023 to 2023. For the full cash flow conversion analysis, see Entrada Therapeutics Inc (TRDA) cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.04x | $139.80 Million | $5.61 Million | — |